Altimmune, Inc. - Common Stock (NQ:ALT)

2.645 -0.015 (-0.56%)

Streaming Delayed Price Updated: 12:22 PM EDT, Jun 10, 2026 Add to My Watchlist

Price and Volume

Volume	1,081,826
Open	2.620
Bid (Size)	2.640 (22,700)
Ask (Size)	2.650 (5,300)
Prev. Close	2.660
Today's Range	2.615 - 2.705
52wk Range	2.560 - 7.730
Shares Outstanding	95,598,665
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗

Today 9:05 EDT

Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug...

Via MarketBeat

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗

June 04, 2026

Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated...

Via MarketBeat

Performance

YTD	-24.6%	-24.6%
1 Month	-14.4%	-14.4%
3 Month	-31.5%	-31.5%
6 Month	-52.1%	-52.1%
1 Year	-55.5%	-55.5%

More News

Altimmune (ALT) Q1 2026 Earnings Transcript ↗

May 13, 2026

Via The Motley Fool

Altimmune Q1 Earnings Call Highlights ↗

May 13, 2026

Via MarketBeat

Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗

March 05, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

May 13, 2026

Via Investor Brand Network

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

From BioMedWire

Via GlobeNewswire

What's going on in today's pre-market session ↗

April 23, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

Via Stocktwits

Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗

January 28, 2026

Via Stocktwits

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Via Stocktwits

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Via Stocktwits

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

Via Stocktwits

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Via Stocktwits

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

October 16, 2025

From Grabar Law Office

Via GlobeNewswire

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 06, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?

Yes, Altimmune, Inc. - Common Stock is publicly traded.

What exchange does Altimmune, Inc. - Common Stock trade on?

Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Altimmune, Inc. - Common Stock?

The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market

What is the current price of Altimmune, Inc. - Common Stock?

The current price of Altimmune, Inc. - Common Stock is 2.645

When was Altimmune, Inc. - Common Stock last traded?

The last trade of Altimmune, Inc. - Common Stock was at 06/10/26 12:22 PM ET

What is the market capitalization of Altimmune, Inc. - Common Stock?

The market capitalization of Altimmune, Inc. - Common Stock is 252.86M

How many shares of Altimmune, Inc. - Common Stock are outstanding?

Altimmune, Inc. - Common Stock has 253M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.